Optura Raises $17.5M Series A to Bring Accountability to Healthcare AI
Optura raised $17.5M in Series A funding led by Salesforce Ventures to scale its ROAI™ platform for healthcare AI measurement and orchestration.
Healthcare spent the last 2 years buying AI the way casinos pump oxygen into the room. Fast. Loud. Slightly disorienting. Boards wanted “AI strategy.” Executives wanted productivity gains. Vendors wanted annual contracts with enough zeroes to make procurement teams sweat through linen shirts. Then the uncomfortable question showed up. What exactly are we getting for all this money?
That question just helped Nashville-based Optura raise $17.5M in Series A funding led by Salesforce Ventures, with participation from Echo Health Ventures, Susa Ventures, Matrix Partners, and HC9 Ventures.The company now has more than $25M in total funding after launching in 2024. Optura is building an enterprise healthcare platform focused on ROAI™, short for Return on AI Investment. The platform helps healthcare organizations evaluate, prioritize, orchestrate, and measure AI initiatives across operational environments that already resemble a regulatory obstacle course designed by sleep-deprived attorneys.
That matters because healthcare AI is entering a new phase. The market is moving away from experimentation theater and toward operational scrutiny. Investors know it. Buyers know it. CFOs definitely know it. The era of “trust us, the AI is cooking” is ending.
What Happened
Optura announced a $17.5M Series A round led by Salesforce Ventures. Echo Health Ventures joined the round while existing investors Susa Ventures, Matrix Partners, and HC9 Ventures increased their support. The company was founded in 2024 by Andy Fanning, Co-Founder and CEO, and Michael Hollis, Co-Founder and President. Both operators came into the market carrying healthcare infrastructure experience instead of the usual startup cosplay where someone discovers healthcare complexity 11 minutes before demo day.
Optura positions itself as an enterprise healthcare AI operating system focused on measurable outcomes. The platform is designed to help healthcare organizations determine which AI initiatives deserve capital allocation, how those initiatives should be deployed, and whether they are producing measurable operational or financial returns. The company says the new funding will be used to expand platform capabilities, deepen AI functionality, grow platform teams, and scale LLM partnerships. That phrasing matters more than it sounds because a lot of healthcare AI startups are still pitching possibility while Optura is pitching operational governance. Those are very different markets.
Why Optura’s ROAI Thesis Matters
Healthcare has a unique talent for turning simple technology conversations into compliance labyrinths with 14 committees, 3 procurement reviews, and a PowerPoint deck nobody survives emotionally intact. That is why the ROAI concept resonates. AI inside healthcare is not just about model performance. It is about implementation friction, workflow integration, auditability, reimbursement pressure, staffing shortages, and operational trust. A chatbot can look brilliant in a product demo and still collapse the second it collides with a live hospital system running on legacy infrastructure held together by institutional trauma and passwords created during the Bush administration.
Optura is targeting that exact pain point. Its platform helps healthcare organizations score AI initiatives, simulate impact before deployment, orchestrate workflows, and track measurable outcomes after implementation. The company is effectively trying to build a financial accountability layer for healthcare AI adoption. That changes the conversation from “Can AI do this?” to “Should we spend money deploying it here?” and that distinction is becoming one of the defining market filters in enterprise AI.
The Investors Are Signaling Something Bigger
Salesforce Ventures leading the round is not random. Large enterprise investors are increasingly looking beyond foundational AI infrastructure and into operational orchestration layers. The market is shifting from raw AI capability toward systems that help enterprises govern, deploy, monitor, and justify AI usage at scale. Healthcare is one of the clearest examples of this transition because the stakes are brutally high. Bad software decisions in healthcare do not just create inefficiency. They create compliance exposure, operational breakdowns, clinician frustration, and financial leakage measured in painful decimal places.
Echo Health Ventures joining the round adds another important signal. Healthcare-focused investors are becoming more selective about AI infrastructure bets. The market no longer rewards generic “AI for healthcare” positioning the way it did 18 months ago when half the industry was throwing the letters GPT into pitch decks like seasoning salt. Investors now want measurable operational frameworks, and that is the lane Optura is trying to own.
Healthcare AI Is Leaving the Experimentation Era
The broader healthcare AI market is starting to divide into 2 camps. One side is still chasing novelty through AI scribes, AI assistants, AI copilots, and wrappers around workflows nobody actually wanted automated in the first place. The other side is building operational infrastructure designed to survive procurement cycles, compliance scrutiny, integration complexity, and enterprise accountability. That second category is becoming far more important.
Healthcare organizations already know AI can generate text, summarize notes, and automate repetitive tasks. The real challenge now is deciding where AI creates durable operational leverage without creating downstream chaos. That is where platforms like Optura enter the conversation. The company’s emphasis on orchestration, prioritization, and measurable return reflects a broader enterprise shift happening across multiple industries. AI buyers are evolving from curiosity-driven purchasing toward finance-driven purchasing. The vibe economy is cooling off. Operators want proof.
What This Signals for Enterprise AI
Optura’s funding round reflects a larger market correction happening across enterprise AI. The first wave of AI adoption rewarded speed. The second wave will reward discipline. Enterprise buyers are becoming less impressed by what AI can theoretically do and more focused on whether deployments survive real-world complexity. That means governance layers, orchestration systems, measurement frameworks, and ROI accountability tools are becoming strategic infrastructure categories instead of supporting utilities.
Healthcare just happens to be the pressure cooker where these realities become visible first, which makes Optura worth watching beyond healthtech. If enterprise AI spending continues tightening around measurable outcomes, ROAI will not remain a healthcare-only conversation. It becomes a boardroom conversation across finance, insurance, logistics, cybersecurity, and enterprise operations. And that changes who wins the next phase of the AI economy.
Frequently Asked Questions
What is Optura?
Optura is a Nashville-based healthcare technology company building an enterprise AI orchestration and ROAI™ platform for healthcare organizations.
How much funding did Optura raise?
Optura raised $17.5M in Series A funding, bringing total funding to more than $25M.
Who led Optura’s Series A round?
Salesforce Ventures led the Series A round. Echo Health Ventures, Susa Ventures, Matrix Partners, and HC9 Ventures also participated.
Who founded Optura?
Optura was founded in 2024 by Andy Fanning and Michael Hollis.
What does ROAI™ mean?
ROAI™ stands for Return on AI Investment. Optura uses the framework to help healthcare organizations evaluate and measure the operational and financial impact of AI deployments.
Why does Optura’s funding matter?
The funding reflects a broader enterprise AI shift toward accountability, orchestration, governance, and measurable operational outcomes rather than experimental AI deployments alone.